Improved response and remission rates in patients receiving IDgenetix-guided medication management for major depressive disorder
In the study, patients whose medication management was guided by IDgenetix achieved a 35% increase in medication response and a 64% increase in remission compared to patients whose medication was not guided by the test
Publication: Poster at 2023 American Psychiatric Association (APA) Annual Meeting
Incorporation of the 40-gene expression profile (40-GEP) test to improve treatment decisions in high-risk cutaneous squamous cell carcinoma (cSCC) patients: case series and algorithm
Cutaneous squamous cell carcinoma (cSCC) has become a significant public health issue due to its rapidly rising incidence and an estimated 1.8 million newly diagnosed cases annually. As with other cancers, treatment decisions for patients with cSCC are based primarily on a patient’s risk for poor outcomes.
Publication: Clinical, Cosmetic and Investigational Dermatology
A tissue systems pathology test enables risk-aligned management of patients with non-dysplastic Barrett’s esophagus: a case series at an expert foregut surgery center
Publication: Podium presentation (643) at DDW 2023, Chicago
A tissue systems pathology test outperforms standard clinicopathic variables in predicting progression in patients with Barrett’s esophagus
Publication: Podium presentation (222) at DDW 2023, Chicago
A tissue systems pathology test enables standardized, risk-aligned management of patients with Barrett’s esophagus
Publication: Poster presentation (Tu1271) at DDW 2023, Chicago
A tissue systems pathology test objectively risk-stratifies patients with Barrett's esophagus: results from a multicenter U.S. clinical experience
Publication: Poster presentation (Tu1272) at DDW 2023, Chicago
A tissue systems pathology test has significant clinical utility to standardize management leading to improved health outcomes for Barrett’s esophagus patients with low-grade dysplasia
Publication: Poster presentation (Tu1270) at DDW 2023, Chicago
Routine imaging guided by a 31-gene expression profile assay results in earlier detection of melanoma with decreased metastatic tumor burden compared to patients without surveillance imaging studies
Evaluating treatment outcomes in pharmacogenomic-guided care for major depression: A rapid review and meta-analysis
Pharmacogenomic (PGx) testing may increase the probability of remission and response in patients with major depressive disorder (MDD) undergoing pharmacotherapy.
Publication: Psychiatry Res
The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study
DecisionDx-Melanoma test results influenced 85% of clinicians’ decisions regarding the SLNB surgical procedure. Use of the test results could help avoid unnecessary procedures in low-risk patients whose tumor biology indicates they could safely forgo the procedure.
Publication: Current Medical Research and Opinion